Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein highly expressed on prostate adenocarcinomas and has been vigorously targeted for both clinical imaging and targeted therapy. Here, FOLH1 is linked to prostate adenocarcinoma.